Skip to main content
. Author manuscript; available in PMC: 2014 Apr 14.
Published in final edited form as: Clin Cancer Res. 2013 Apr 29;19(12):3201–3211. doi: 10.1158/1078-0432.CCR-12-3751

Figure 4.

Figure 4

CDO1-induced reduction in ROS detoxification sensitizes breast cancer cells to anthracycline treatment. A, cell viability of doxycycline-induced/not doxycycline-induced CDO1-stable MDA-MB-231 cells before and 48 hours after treatment with different doses of anthracycline (doxorubicin) was measured by MTS assay. Data presented are the mean of 2 independent experiments ± SEM. Group comparisons were carried out using Student t test. *, P < 0.05. B, ROS production, using CM-H2DCFDA probe and cell viability of same cells before and 48 hours after treatment with 0.078 μmol/L doxorubicin was measured. Data presented are the mean of 2 independent experiments ± SEM. Obtained values for A and B were normalized to anthracycline-untreated or -treated doxycycline-induced/not doxycycline-induced empty vector control cells and plotted as % relative to anthracycline-untreated and not doxycycline-induced MDA-MB-231-CDO1-WT cells. Group comparisons were carried out using Student t test. *, P < 0.05; n.s., not significant.